Status:
RECRUITING
An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborating Sponsors:
Baxter Healthcare Corporation
Conditions:
End Stage Renal Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Investigators know that many patients who are on dialysis suffer from burden of unwanted symptoms, which can affect quality of life. The understanding and treatment of symptom burden by healthcare pro...
Detailed Description
Baxter Canada has an expanded hemodialysis (HDx) membrane called the "Theranova", which is capable of removing solutes of higher molecular weight. Although this clearly has biochemical advantages it i...
Eligibility Criteria
Inclusion
- Conventional thrice weekly HD schedule
- Must be on chronic hemodialysis for at least 3 months
- Age ≥18 years
- Willing and able to give informed consent
Exclusion
- Active infection (may enroll once infection is cleared)
- Patients receiving daily hemodialysis treatment
- Patients currently receiving Hemodiafiltration (HDF), Hemofiltration (HF) or Isolated ultrafiltration (ISO UF) more than once in three months
- Visual impairment
- History of neurocognitive impairment
- History of stroke (CVA)
Key Trial Info
Start Date :
March 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06032208
Start Date
March 1 2024
End Date
December 31 2025
Last Update
February 6 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Victoria Hospital, London Health Sciences Centre
London, Ontario, Canada, N6A 5W9
2
Westmount Kidney Care Centre
London, Ontario, Canada, N6K 1M6